FDA Grants Accelerated Approval for Vera Therapeutics' TRUTAKNA in IgA Nephropathy
VERA has more than doubled off its 52-week low of $19.066.
Summary
Vera Therapeutics has received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to treat primary IgA Nephropathy. This approval was based on a statistically significant 42% reduction in proteinuria compared to placebo in the ORIGIN 3 trial, following the company's June 2nd announcement of FDA alignment on an accelerated timeline for the drug's submission. TRUTAKNA is notable as the first and only BAFF and APRIL inhibitor approved for this serious kidney disease, which affects an estimated 160,000 patients in the U.S., indicating a significant market opportunity. Continued approval remains contingent on verification of clinical benefit, with eGFR results from the ongoing ORIGIN 3 trial anticipated in Q3 2026.
At the time of this announcement, VERA was trading at $42.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $19.07 to $56.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.